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defects	 in	 insulin	 secretion,	 insulin	 action,	 or	 both.	 The	 chronic	 hyperglycemia	 of	 diabetes	 is	
associated	with	long-term	damage,	dysfunction,	and	failure	of	various	organs,	especially	the	eyes,	
kidneys,	 nerves,	 heart,	 and	 blood	 vessels.	 Several	 pathogenic	 processes	 are	 involved	 in	 the	
development	 of	 diabetes.	 These	 range	 from	 autoimmune	 destruction	 of	 the	 β-cells	 of	 the	
pancreas	with	 consequent	 insulin	 deficiency	 to	 abnormalities	 that	 result	 in	 resistance	 to	 insulin	
action.	The	basis	of	the	abnormalities	in	carbohydrate,	fat,	and	protein	metabolism	in	diabetes	is	
deficient	action	of	insulin	on	target	tissues.	Deficient	insulin	action	results	from	inadequate	insulin	
secretion	 and/or	 diminished	 tissue	 responses	 to	 insulin	 at	 one	 or	 more	 points	 in	 the	 complex	
pathways	 of	 hormone	 action.	 Impairment	 of	 insulin	 secretion	 and	 defects	 in	 insulin	 action	
frequently	coexist	in	the	same	patient,	and	it	is	often	unclear	which	abnormality,	if	either	alone,	is	




Acute,	 life-threatening	 consequences	 of	 uncontrolled	 diabetes	 are	 hyperglycemia	 with	
ketoacidosis	or	the	nonketotic	hyperosmolar	syndrome.	
	
Long-term	 complications	 of	 diabetes	 include	 retinopathy	 with	 potential	 loss	 of	 vision;	
nephropathy	leading	to	renal	failure;	peripheral	neuropathy	with	risk	of	foot	ulcers,	amputations,	
and	 Charcot	 joints;	 and	 autonomic	 neuropathy	 causing	 gastrointestinal,	 genitourinary,	 and	
cardiovascular	symptoms	and	sexual	dysfunction.	Diabetic	patients	have	an	increased	incidence	of	
atherosclerotic	cardiovascular,	peripheral	arterial,	and	cerebrovascular	disease.	Hypertension	and	
abnormalities	 of	 lipoprotein	 metabolism	 are	 often	 found	 in	 people	 with	 diabetes.	 The	 vast	
majority	of	cases	of	diabetes	fall	into	two	broad	etiopathogenetic	categories:	
- In	one	category,	 type	1	diabetes,	 the	cause	 is	an	absolute	deficiency	of	 insulin	secretion.	
Individuals	at	increased	risk	of	developing	this	type	of	diabetes	can	often	be	identified	by	
serological	 evidence	 of	 an	 autoimmune	 pathologic	 process	 occurring	 in	 the	 pancreatic	
islets	and	by	genetic	markers.	
- In	 type	 2	 diabetes,	 the	 cause	 is	 a	 combination	 of	 resistance	 to	 insulin	 action	 and	 an	
inadequate	 compensatory	 insulin	 secretory	 response.	 In	 the	 latter	 category,	 a	 degree	 of	
hyperglycemia	 sufficient	 to	 cause	 pathologic	 and	 functional	 changes	 in	 various	 target	
tissues,	 but	without	 clinical	 symptoms,	may	be	present	 for	 a	 long	period	of	 time	before	
diabetes	 is	 detected.	 During	 this	 asymptomatic	 period,	 it	 is	 possible	 to	 demonstrate	 an	
abnormality	in	carbohydrate	metabolism	by	measurement	of	plasma	glucose	in	the	fasting	
state	or	after	a	challenge	with	an	oral	glucose	 load.	The	degree	of	hyperglycemia	(if	any)	
may	 change	 over	 time,	 depending	 on	 the	 extent	 of	 the	 underlying	 disease	 process.	 A	





require	 insulin.	 Other	 individuals	 who	 have	 some	 residual	 insulin	 secretion	 but	 require	






2. CLASSIFICATION	 OF	 DIABETES	 MELLITUS	 AND	 OTHER	 CATEGORIES	 OF	 GLUCOSE	
REGULATION	
Assigning	a	 type	of	diabetes	 to	an	 individual	often	depends	on	the	circumstances	present	at	
the	 time	of	 diagnosis,	 and	many	diabetic	 individuals	 do	not	 easily	 fit	 into	 a	 single	 class.	 For	
example,	a	person	with	gestational	diabetes	mellitus	(GDM)	may	continue	to	be	hyperglycemic	
after	delivery	and	may	be	determined	to	have,	in	fact,	type	2	diabetes.	Alternatively,	a	person	
who	 acquires	 diabetes	 because	 of	 large	 doses	 of	 exogenous	 steroids	 may	 become	
normoglycemic	 once	 the	 glucocorticoids	 are	 discontinued,	 but	 then	 may	 develop	 diabetes	
many	years	later	after	recurrent	episodes	of	pancreatitis.	Another	example	would	be	a	person	
treated	 with	 thiazides	 who	 develops	 diabetes	 years	 later.	 Because	 thiazides	 in	 themselves	
seldom	 cause	 severe	 hyperglycemia,	 such	 individuals	 probably	 have	 type	 2	 diabetes	 that	 is	




Type	 1	 diabetes	 (β-cells	 destruction,	 usually	 leading	 to	 absolute	 insulin	 deficiency)	 Immune-
mediated	diabetes.	




autoantibodies	 to	 glutamic	 acid	 decarboxylase	 (GAD65),	 and	 autoantibodies	 to	 the	 tyrosine	
phosphatases	 IA-2	and	 IA-2β .	One	and	usually	more	of	 these	autoantibodies	are	present	 in	85–
90%	of	 individuals	when	 fasting	hyperglycemia	 is	 initially	detected.	Also,	 the	disease	has	 strong	
HLA	associations,	with	linkage	to	the	DQA	and	DQB	genes,	and	it	is	influenced	by	the	DRB	genes.	
These	HLA-DR/DQ	alleles	 can	be	either	predisposing	or	protective.	 In	 this	 form	of	diabetes,	 the	
rate	 of	β-cells	 destruction	 is	 quite	 variable,	 being	 rapid	 in	 some	 individuals	 (mainly	 infants	 and	
children)	and	slow	in	others	(mainly	adults).	Some	patients,	particularly	children	and	adolescents,	
may	 present	 with	 ketoacidosis	 as	 the	 first	 manifestation	 of	 the	 disease.	 Others	 have	 modest	
fasting	hyperglycemia	that	can	rapidly	change	to	severe	hyperglycemia	and/or	ketoacidosis	in	the	
presence	 of	 infection	 or	 other	 stress.	 Still	 others,	 particularly	 adults,	may	 retain	 residual	β-cell	
function	 sufficient	 to	 prevent	 ketoacidosis	 for	 many	 years;	 such	 individuals	 eventually	 become	
dependent	on	insulin	for	survival	and	are	at	risk	for	ketoacidosis.	At	this	latter	stage	of	the	disease,	
there	 is	 little	 or	 no	 insulin	 secretion,	 as	manifested	 by	 low	or	 undetectable	 levels	 of	 plasma	C-
peptide.	 Immunemediated	 diabetes	 commonly	 occurs	 in	 childhood	 and	 adolescence,	 but	 it	 can	
occur	at	any	age,	even	in	the	8th	and	9th	decades	of	life.	Autoimmune	destruction	of	β-cells	has	
multiple	genetic	predispositions	and	 is	also	related	to	environmental	 factors	 that	are	still	poorly	
defined.	 Although	 patients	 are	 rarely	 obese	 when	 they	 present	 with	 this	 type	 of	 diabetes,	 the	
presence	of	obesity	is	not	incompatible	with	the	diagnosis.	These	patients	are	also	prone	to	other	
autoimmune	disorders	such	as	Graves’	disease,	Hashimoto’s	thyroiditis,	Addison’s	disease,	vitiligo,	





ketoacidosis	 and	 exhibit	 varying	 degrees	 of	 insulin	 deficiency	 between	 episodes.	 This	 form	 of	










to	 survive.	 There	 are	 probably	 many	 different	 causes	 of	 this	 form	 of	 diabetes.	 Although	 the	
specific	etiologies	are	not	known,	autoimmune	destruction	of	β-cells	does	not	occur,	and	patients	
do	not	have	any	of	 the	other	 causes	of	diabetes	 listed	above	or	below.	Most	patients	with	 this	
form	of	diabetes	are	obese,	and	obesity	 itself	causes	some	degree	of	 insulin	resistance.	Patients	









function	 been	 normal.	 Thus,	 insulin	 secretion	 is	 defective	 in	 these	 patients	 and	 insufficient	 to	
compensate	 for	 insulin	 resistance.	 Insulin	 resistance	may	 improve	with	weight	 reduction	and/or	
pharmacological	 treatment	 of	 hyperglycemia	 but	 is	 seldom	 restored	 to	 normal.	 The	 risk	 of	
developing	this	form	of	diabetes	increases	with	age,	obesity,	and	lack	of	physical	activity.	It	occurs	
more	frequently	in	women	with	prior	GDM	and	in	individuals	with	hypertension	or	dyslipidemia,	
and	its	frequency	varies	 in	different	racial/	ethnic	subgroups.	 It	 is	often	associated	with	a	strong	






of	 diabetes	 are	 frequently	 characterized	 by	 onset	 of	 hyperglycemia	 at	 an	 early	 age	 (generally	
before	age	25	years).	They	are	referred	to	as	maturityonset	diabetes	of	the	young	(MODY)	and	are	
characterized	by	impaired	insulin	secretion	with	minimal	or	no	defects	in	insulin	action.	They	are	
inherited	 in	 an	 autosomal	 dominant	 pattern.	 Abnormalities	 at	 six	 genetic	 loci	 on	 different	
chromosomes	have	been	identified	to	date.	The	most	common	form	is	associated	with	mutations	
on	 chromosome	 12	 in	 a	 hepatic	 transcription	 factor	 referred	 to	 as	 hepatocyte	 nuclear	 factor	
(HNF)-1.	A	second	form	is	associated	with	mutations	in	the	glucokinase	gene	on	chromosome	7p	
and	 results	 in	 a	 defective	 glucokinase	 molecule.	 Glucokinase	 converts	 glucose	 to	 glucose-6-
phosphate,	 the	 metabolism	 of	 which,	 in	 turn,	 stimulates	 insulin	 secretion	 by	 the	 β-cell.	 Thus,	
glucokinase	 serves	 as	 the	 “glucose	 sensor”	 for	 the	β-cell.	 Because	of	 defects	 in	 the	 glucokinase	
gene,	increased	plasma	levels	of	glucose	are	necessary	to	elicit	normal	levels	of	insulin	secretion.	
The	 less	 common	 forms	 result	 from	 mutations	 in	 other	 transcription	 factors,	 including	 HNF-4,	
HNF-1 ,	insulin	promoter	factor	(IPF)-1,	and	NeuroD1.	Point	mutations	in	mitochondrial	DNA	have	
been	 found	 to	 be	 associated	with	 diabetes	mellitus	 and	 deafness.	 The	most	 common	mutation	
occurs	 at	 position	 3243	 in	 the	 tRNA	 leucine	 gene,	 leading	 to	 an	 A-to-G	 transition.	 An	 identical	
lesion	occurs	 in	 the	MELAS	 syndrome	 (mitochondrial	myopathy,	encephalopathy,	 lactic	acidosis,	
and	 stroke-like	 syndrome);	 however,	 diabetes	 is	 not	part	 of	 this	 syndrome,	 suggesting	different	
phenotypic	expressions	of	this	genetic	lesion.	Genetic	abnormalities	that	result	in	the	inability	to	
convert	proinsulin	to	insulin	have	been	identified	in	a	few	families,	and	such	traits	are	inherited	in	
an	 autosomal	 dominant	 pattern.	 The	 resultant	 glucose	 intolerance	 is	 mild.	 Similarly,	 the	
production	 of	mutant	 insulin	molecules	with	 resultant	 impaired	 receptor	 binding	 has	 also	 been	










Rabson-Mendenhall	 syndrome	 are	 two	 pediatric	 syndromes	 that	 have	 mutations	 in	 the	 insulin	
receptor	 gene	 with	 subsequent	 alterations	 in	 insulin	 receptor	 function	 and	 extreme	 insulin	
resistance.	The	 former	has	characteristic	 facial	 features	and	 is	usually	 fatal	 in	 infancy,	while	 the	
latter	is	associated	with	abnormalities	of	teeth	and	nails	and	pineal	gland	hyperplasia.	Alterations	
in	 the	 structure	 and	 function	 of	 the	 insulin	 receptor	 cannot	 be	 demonstrated	 in	 patients	 with	




Any	 process	 that	 diffusely	 injures	 the	 pancreas	 can	 cause	 diabetes.	 Acquired	 processes	 include	
pancreatitis,	trauma,	infection,	pancreatectomy,	and	pancreatic	carcinoma.	With	the	exception	of	
that	 caused	 by	 cancer,	 damage	 to	 the	 pancreas	 must	 be	 extensive	 for	 diabetes	 to	 occur;	
adrenocarcinomas	 that	 involve	 only	 a	 small	 portion	 of	 the	 pancreas	 have	 been	 associated	with	







Several	 hormones	 (e.g.,	 growth	 hormone,	 cortisol,	 glucagon,	 epinephrine)	 antagonize	 insulin	
action.	Excess	amounts	of	these	hormones	(e.g.,	acromegaly,	Cushing’s	syndrome,	glucagonoma,	
pheochromocytoma,	 respectively)	 can	 cause	 diabetes.	 This	 generally	 occurs	 in	 individuals	 with	
pre-existing	defects	 in	 insulin	secretion,	and	hyperglycemia	typically	resolves	when	the	hormone	
excess	 is	 resolved.	 Somatostatinoma-	 and	 aldosteronoma-induced	 hypokalemia	 can	 cause	







is	 unknown.	 Certain	 toxins	 such	 as	 Vacor	 (a	 rat	 poison)	 and	 intravenous	 pentamidine	 can	
permanently	destroy	pancreatic	β-cells.	There	are	also	many	drugs	and	hormones	that	can	impair	





Certain	 viruses	 have	 been	 associated	 with	β-cells	 destruction.	 Diabetes	 occurs	 in	 patients	 with	
congenital	rubella,	although	most	of	these	patients	have	HLA	and	immune	markers	characteristic	




In	 this	 category,	 there	 are	 two	 known	 conditions,	 and	 others	 are	 likely	 to	 occur.	 The	 stiff-man	
syndrome	is	an	autoimmune	disorder	of	the	central	nervous	system	characterized	by	stiffness	of	
the	axial	muscles	with	painful	spasms.	Patients	usually	have	high	titers	of	the	GAD	autoantibodies,	
and	 approximately	 one-third	 will	 develop	 diabetes.	 Anti–insulin	 receptor	 antibodies	 can	 cause	
diabetes	by	binding	to	the	insulin	receptor,	thereby	blocking	the	binding	of	insulin	to	its	receptor	
in	 target	 tissues.	 However,	 in	 some	 cases,	 these	 antibodies	 can	 act	 as	 an	 insulin	 agonist	 after	
binding	to	the	receptor	and	can	thereby	cause	hypoglycemia.	Anti–insulin	receptor	antibodies	are	
occasionally	 found	 in	 patients	 with	 systemic	 lupus	 erythematosus	 and	 other	 autoimmune	






These	 include	 the	chromosomal	abnormalities	of	Down’s	 syndrome,	Klinefelter’s	 syndrome,	and	





GDM	 is	 defined	 as	 any	 degree	 of	 glucose	 intolerance	 with	 onset	 or	 first	 recognition	 during	
pregnancy.	The	definition	applies	 regardless	of	whether	 insulin	or	only	diet	modification	 is	used	
for	treatment	or	whether	the	condition	persists	after	pregnancy.	It	does	not	exclude	the	possibility	







The	Expert	Committee	 (1,2)	 recognized	an	 intermediate	group	of	 subjects	whose	glucose	 levels,	
although	 not	meeting	 criteria	 for	 diabetes,	 are	 nevertheless	 too	 high	 to	 be	 considered	 normal.	














are	 not	 clinical	 entities	 in	 their	 own	 right	 but	 rather	 risk	 factors	 for	 future	 diabetes	 as	 well	 as	
cardiovascular	disease.	 IFG	and	 IGT	are	associated	with	the	metabolic	syndrome,	which	 includes	
obesity	(especially	abdominal	or	visceral	obesity),	dyslipidemia	of	the	high-triglyceride	and/or	low-
HDL	 type,	 and	 hypertension.	 It	 is	 worth	 mentioning	 that	 medical	 nutrition	 therapy	 aimed	 at	
producing	 5–10%	 loss	 of	 body	weight,	 exercise,	 and	 certain	 pharmacological	 agents	 have	 been	
variably	demonstrated	to	prevent	or	delay	 the	development	of	diabetes	 in	people	with	 IGT;	 the	
potential	 impact	 of	 such	 interventions	 to	 reduce	 cardiovascular	 risk	 has	 not	 been	 examined	 to	
date.	Note	that	many	individuals	with	IGT	are	euglycemic	in	their	daily	lives.	Individuals	with	IFG	or	









of	 Carpenter	 and	 Coustan.	 Recommendations	 from	 the	 American	Diabetes	 Association’s	 Fourth	
International	WorkshopConference	on	Gestational	Diabetes	Mellitus	held	in	March	1997	support	
the	use	of	the	Carpenter/Coustan	diagnostic	criteria	as	well	as	the	alternative	use	of	a	diagnostic	










●	 are	 not	members	 of	 an	 ethnic/racial	 group	with	 a	 high	prevalence	of	 diabetes	 (e.g.,	Hispanic	
American,	Native	American,	Asian	American,	African	American,	Pacific	Islander).	
Risk	 assessment	 for	 GDM	 should	 be	 undertaken	 at	 the	 first	 prenatal	 visit.	Women	with	 clinical	
characteristics	 consistent	 with	 a	 high	 risk	 of	 GDM	 (marked	 obesity,	 personal	 history	 of	 GDM,	
glycosuria,	or	a	strong	 family	history	of	diabetes)	should	undergo	glucose	testing	 (see	below)	as	
soon	 as	 feasible.	 If	 they	 are	 found	 not	 to	 have	 GDM	 at	 that	 initial	 screening,	 they	 should	 be	
retested	 between	 24	 and	 28	 weeks	 of	 gestation.	 Women	 of	 average	 risk	 should	 have	 testing	
undertaken	at	24	–28	weeks	of	gestation.	A	fasting	plasma	glucose	level	>126	mg/dl	(7.0	mmol/l)	
or	 a	 casual	 plasma	 glucose	 >200	mg/dl	 (11.1	mmol/l)	meets	 the	 threshold	 for	 the	 diagnosis	 of	
diabetes.	 In	 the	 absence	 of	 unequivocal	 hyperglycemia,	 the	 diagnosis	must	 be	 confirmed	 on	 a	




The	 one-step	 approach	 may	 be	 cost-effective	 in	 high-risk	 patients	 or	 populations	 (e.g.,	 some	
NativeAmerican	groups).	
Two-step	 approach:	 perform	 an	 initial	 screening	 by	 measuring	 the	 plasma	 or	 serum	 glucose	
concentration	 1	 h	 after	 a	 50-g	 oral	 glucose	 load	 (glucose	 challenge	 test	 [GCT])	 and	 perform	 a	
diagnostic	 OGTT	 on	 that	 subset	 of	 women	 exceeding	 the	 glucose	 threshold	 value	 on	 the	 GCT.	
When	the	two-step	approach	is	used,	a	glucose	threshold	value	>140	mg/dl	(7.8	mmol/l)	identifies	
80%	 of	women	with	GDM,	 and	 the	 yield	 is	 further	 increased	 to	 90%	 by	 using	 a	 cutoff	 of	 >130	
mg/dl	(7.2	mmol/l).	With	either	approach,	the	diagnosis	of	GDM	is	based	on	an	OGTT.	Diagnostic	
criteria	 for	 the	 100-g	 OGTT	 are	 derived	 from	 the	 original	 work	 of	 O’Sullivan	 and	 Mahan	 (4)	
modified	 by	 Carpenter	 and	 Coustan	 (3)	 and	 are	 shown	 in	 the	 top	 of	 Table	 3.	 Alternatively,	 the	
diagnosis	 can	 be	 made	 using	 a	 75-g	 glucose	 load	 and	 the	 glucose	 threshold	 values	 listed	 for	













as	 described	 by	WHO,	 using	 a	 glucose	 load	 containing	 the	 equivalent	 of	 75	 g	 anhydrous	 glucose	
dissolved	in	water.	In	the	absence	of	unequivocal	hyperglycemia,	these	criteria	should	be	confirmed	











the	 Framingham	 study	 firmly	 established	 the	 epidemiologic	 link	 between	 diabetes	 and	 HF,	












the	 effects	 of	 lipotoxicity,	 microvascular	 AGEs	 deposition,	 microvascular	 rarefaction,	 and	

























ventricular	 (LV)	 remodeling	 and	 dysfunction	 consist	 of	 coronary	 microvascular	 endothelial	
dysfunction	 and	 cardiomyocyte	 cell	 death	 for	 HFPEF	 and	 HFREF,	 respectively.	 Similarly,	 the	
preference	of	endothelial	or	cardiomyocyte	cell	compartments	 in	DM	patients	could	explain	 the	
development	of	DCM	into	two	subtypes,	restrictive/HFPEF	or	dilated/HFREF	phenotypes.	Diabetes	
mellitus-induced	 metabolic	 derangements	 such	 as	 hyperglycemia,	 lipotoxicity,	 and	
hyperinsulinemia	 favor	 development	 of	 DCM	 with	 the	 restrictive/HFPEF	 type,	 which	 is	 more	
prevalent	 in	 obesity.	 In	 contrast,	 autoimmunity	 predisposes	 to	 the	 dilated/HFREF	 phenotype,	
which	 manifests	 itself	 more	 in	 type	 1	 DM.	 Finally,	 coronary	 microvascular	 rarefaction	 and	










growth	 and	 cardiac	 hypertrophy	 and	 these	 damaging	 effects	 can	 be	 further	 aggravated	 by	
oxidative	 stress.	 In	 addition,	 it	 stimulates	 collagen	 production	 and	 crosslinking	 as	 well	 as	 the	
production	and	deposition	of	non-enzymatic	formation	of	advanced	glycation	end-products	(AGEs)	
in	 the	 coronary	 microvasculature	 and	 the	 myocardial	 interstitium.	 AGEs	 trigger	 vascular	
inflammation,	 lower	myocardial	 NO	 bioavailability	 and	 contribute	 to	 concentric	 LV	 remodeling.	
AGEs-induced	crosslinking	in	collagen	and	elastin	and	result	in	increased	myocardial	stiffness	and	







reactive	 interstitial	 fibrosis	 and	 expression	 of	 myocardial	 titin,	 all	 of	 which	 contribute	 to	 the	
reduction	 in	 cardiomyocyte	distensibility.	 Central	 obesity	 (associated	with	 IR)	 and	microvascular	
rarefaction	cause	the	release	of	proinflammatory	cytokines	and	the	generation	of	reactive	oxygen	
species	(ROS),	leading	to	an	inflammatory	state	in	the	coronary	microvasculature	with	a	reduction	
in	 nitric	 oxide	 (NO)	 bioavailability,	 increased	 vessel	 permeability	 and	 programmed	 cell	 death	
(apoptosis).	 This	 coronary	 microvascular	 endothelial	 dysfunction	 is	 thought	 to	 drive	 the	




utilization	 from	glucose	 to	 free	 fatty	acids.	 It	 impairs	myocardial	glucose	utilization	and	 leads	 to	
excess	 fatty	 acid	uptake	 into	 cardiomyocytes	 and	eventually	 induces	mitochondrial	 dysfunction,	
reduction	in	ATP	availability	and	eventual	cell	death	(lipotoxicity).	The	defect	in	myocardial	energy	
production	impairs	myocyte	contractile	function,	manifesting	initially	as	diastolic	function.	Excess	




Several	 factors:	 reduced	 NO	 production,	 AGEs-	 mediated	 stiffening	 of	 coronary	 media,	 and	
perivascular	 fibrosis,	 contribute	 to	 a	 reduction	 in	 coronary	 flow	 reserve.	 In	 addition,	
cardiomyocyte	 hypertrophy	 is	 associated	 with	 a	 reduction	 in	 capillary	 density	 (microvascular	
rarefaction)	that	leads	to	impaired	myocardial	perfusion,	lowers	NO	bioavailability	and	contributes	
to	myocardial	stiffness	that	is	typical	of	diastolic	dysfunction.	Tissue	hypoxia	results	in	the	further	











with	nephropathy,	but	with	widespread	microvascular	disease,	 including	the	heart.	 In	 the	heart,	
diabetic	autonomic	neuropathy	contributes	to	impaired	autoregulation	and	lack	of	flow	reserve,	a	





that	 this	 immune	 response,	 combined	 with	 the	 effects	 of	 worsening	 tissue	 hypoxia	 described	
above,	 probably	 provide	 the	 stimulus	 to	 the	 development	 of	 eccentric	 ventricular	 remodeling,	
resulting	 in	 ventricular	 dilatation	 and	 systolic	 dysfunction	 leading	 to	 the	 picture	 of	 dilated	
cardiomyopathy	that	has	been	described	in	type	1DM.	
2.	Development	of	myocardial	dysfunction	
As	 explained	 above,	 excess	 chronic	 oxidative	 stress	 produced	 by	 the	 release	 of	 ROS	 from	 the	
mitochondria	and	from	proinflammatory	cytokines	and	leucocytes,	cause	direct	damage	to	plasma	
membrane	 cell	 organelles	 leading	 to	 myocardial	 damage.	 This	 may	 account	 for	 the	 increased	
oxidative	 injury	 resulting	 in	 the	 excessive	morbidity	 and	mortality	 after	myocardial	 infarction	 in	
patients	 with	 diabetes	 when	 compared	 to	 patients	 without	 diabetes.	 Oxidative	 stress	 is	 the	
unifying	 factor	 in	 the	 development	 of	 diabetes-related	 cardiac	 complications,	 including	
atherosclerosis	(Figure	1).	
Myocardial	 damage	 in	 the	absence	of	 epicardial	 coronary	disease	 (macrovascular)	 is	most	 likely	
related	to	microvascular	dysfunction,	leading	to	diabetic	cardiomyopathy	(DMCMO).	








model	 of	 diabetic	 cardiomyopathy	 has	 been	 proposed.	 In	 a	 recent	 review	 Seferovic	 and	 Paulus	
proposed	that	the	deposition	of	AGEs	in	the	myocardium	and	coronary	microvascular	rarefaction	











Because	 of	 the	 structural	 and	 functional	 changes	 that	 occur	 in	 DMCMO,	 subjects	 develop	
functional	changes	early	in	the	course	of	their	disease.	Diastolic	dysfunction	is	the	most	frequent	






(35±9	 years);	 they	 had	 higher	 blood	 pressure	 and	 a	 higher	 prevalence	 of	 albuminuria	 and	
retinopathy	than	those	without	heart	 failure.	Diabetic	patients	with	microvascular	complications	
showed	 the	 strongest	 association	 with	 cardiomyopathy	 and	 this	 relationship	 paralleled	 the	
duration	 and	 severity	 of	 hyperglycemia.	 These	 findings	 have	 been	 confirmed	 in	 a	 recent	 large	




Asymptomatic	 diastolic	 dysfunction	 offers	 an	 opportunity	 for	 the	 primary	 prevention	 of	 heart	
failure	 in	 at-risk	 diabetic	 subjects	 if	 changes	 can	 be	 detected	 early	 and	 appropriate	 therapy	
instituted.	 Since	 there	 is	 little	 evidence	 to	 support	 the	use	of	 biomarkers	 in	 detecting	 the	early	
stages	 of	 DMCMO,	 a	 strategy	 of	 screening	 asymptomatic	 diabetic	 subjects	 for	 impaired	 LV	
function	with	natriuretic	peptides	 is	 not	 recommended.	 It	 is	 suggested	 that	diabetic	 subjects	 at	
risk	 of	 developing	 DMCMO	 (such	 as	 those	with	 atrial	 fibrillation,	microalbuminuria/proteinuria,	





prevention	 of	 heart	 failure	 in	 diabetes.	 There	 is	 evidence	 that	 glycemic	 control	 and	 lifestyle	
measures	 started	 earlier	 in	 the	 course	 of	 the	 IR	 spectrum	 (early	 diabetes,	 prediabetes	 and	
metabolic	 syndrome)	 could	 address	 the	metabolic	milieu	 before	 they	 have	 become	 established	
and	 may	 be	 beneficial.	 In	 this	 respect	 the	 Diabetes	 Control	 and	 Complications	 Trial	
(DCCT)/Epidemiology	 of	 Diabetes	 Interventions	 and	 Complications	 (EDIC)	 study	 has	 shown	 that	




with	 diabetes	 cannot	 be	 attributed	 to	 any	 other	 known	 cardiovascular	 disease.	 Metabolic	 and	
microvascular	 mechanisms	 contribute	 to	 the	 pathogenesis.	 At	 a	 subcellular	 level	 in	 the	
mitochondrion,	oxidative	stress,	coupled	with	loss	of	normal	microvessels	and	remodeling	of	the	
extracellular	 matrix,	 lead	 to	 an	 inflammatory	 state	 with	 decline	 in	 cardiomyocyte	 contractile	
function.	 The	 disease	 course	 consists	 of	 a	 hidden	 subclinical	 period,	 during	 which	 endothelial	







Diagnosis	 of	 DCM	 requires	 impairment	 of	 the	 glucose	metabolism	 and	 a	 thorough	 approach	 to	
exclude	 other	 causes	 of	 ventricular	 dysfunction	 such	 as	 coronary,	 valvular,	 hypertensive,	 or	
congenital	 heart	 disease	 and	 infections	 such	 as	 viral	 myocarditis	 or	 toxins-induced,	 familial	 or	
infiltrative	 cardiomyopathies.	 Although	 the	 chief	 cause	 of	 DCM	 is	 diabetes,	 the	 following	 risk	
factors	which	might	exacerbate	DCM	need	special	attention:	obesity,	chronic	high	blood	glucose,	
high	blood	pressure,	dyslipidemia,	smoking	and	alcohol	consumption.	
A	 relevant	 diagnostic	 approach	 should	 be	 employed	 to	 diagnose	 DCM,	 which	 should	 include	 a	
thorough	 history	 and	 a	 proper	 physical	 examination:	 relevant	 investigative	 approach	 including	
urine	analysis	to	test	for	the	presence	of	proteinuria,	stress	test,	chest	X-ray,	electrocardiography	
and	echocardiography	(Table	3).	 Invasive	measures	should	also	be	considered	in	some	situations	












• Serum	 aminoterminal	 propeptide	 of	 type	 I	 and	 type	 III	 collagens,	 and	
carboxyterminal	telopeptide	of	type	I	collagen	
























apply	 a	 high-velocity	 low-amplitude	 filter	 to	 the	 myocardium,	 enabling	 an	 assessment	 of	
myocardial	 tissue	 velocities	 with	 relative	 ease.	 The	 advantage	 of	 TDI	 over	 standard	 Doppler	
echocardiographic	 indices	 is	 that	 the	results	are	 independent	of	changes	 in	ventricular	pre-load.	




diastolic	 function.	 STE	 has	 improved	 the	 quantitative	 assessment	 of	 regional	 or	 segmental	wall	
motion	and	also	the	accuracy	and	reproducibility	of	test	readings.	STE	is	a	new	advanced	imaging	
tool	 which	 is	 highly	 sensitive	 and	 reproducible	 to	 evaluate	 subtle	 features	 of	 ventricular	





Contrast	 echocardiography	 is	 useful	 in	 current	 clinical	 practice	 as	 proper	 delineation	 of	 the	
endocardial	border	observed	after	contrast	administration	increases	the	clarity	of	the	images	and	
improves	 the	 results	 provided	 by	 the	 algorithms	 orientated	 to	 the	 assessment	 of	 ventricular	
motion.	Moreover,	direct	assessment	of	myocardial	blood	flow	and	flow	reserve	 is	possible	with	
contrast	 echocardiography,	 as	 microbubble	 contrast	 agents	 remain	 entirely	 within	 the	
intravascular	space.	In	any	myocardial	segment,	contrast	echocardiography	denotes	the	status	of	










Similarly,	 coronary	 artery	 calcification	 (CAC)	 can	 increase	 significantly	 in	 asymptomatic	 patients	
with	 long-standing	 type	 2	 DM	 compared	 with	 non-diabetic	 subjects.	 The	 CAC	 score,	 derived	
originally	 from	electron-beam	computed	tomography	(CT)	and	more	recently	 from	multislice	CT,	
correlates	 strongly	with	 the	 presence	 and	 severity	 of	 histological	 and	 angiographic	 evidence	 of	
coronary	 atherosclerosis	 and	 conventional	 coronary	 heart	 disease	 risk	 factors,	 in	 particular	 C-
reactive	protein,	reflecting	stable	and	unstable	plaques.	
5.3	Magnetic	resonance	
Cardiac	 MRI	 has	 recently	 emerged	 as	 a	 useful	 imaging	 tool	 for	 structural	 and	 functional	
myocardium	disorders.	It	is	also	an	important	non-invasive	modality	to	detect	diastolic	dysfunction	
and	myocardial	steatosis	in	DM	and	other	pathological	myocardial	disease.	

































This	 technique	 it	 does	 not	 work	 equally	 in	 the	 detection	 of	 diffuse	 fibrosis	 is	 burden	 by	 the	
operator	dependence.	
T1	mapping	







normal	 tissue	 falls	within	a	predictable	 range	 (at	1.5	T,	normal	myocardium	has	a	T1	 relaxation	
















native	 T1	 times),	 equipment	 manufacturer,	 and	 the	 type	 of	 mapping	 sequence	 used.	 Several	
recent	 publications	 have	 reported	 “normal”	 T1	 ranges	 for	 healthy	 subjects;	 these	 ranges	 are	
discussed	later	in	the	article.	By	providing	a	reproducible	standard	of	T1	and	T2	values,	myocardial	
mapping	may	reduce	interpretation	variability	and	error	related	to	subjective	analysis	and	image	




altering	 the	 native	 T1	 and	 T2	 signals.	 In	 general,	 a	 prolonged	 native	 myocardial	 T1	 signal	 is	
encountered	in	various	disease	states	that	result	in	edema	or	fibrosis,	and	in	amyloid	deposition.	
Shortening	of	 the	native	T1	 relaxation	 time	can	be	seen	with	siderosis,	Anderson-Fabry	disease,	
and	fat	deposition,	although	these	diseases	are	less	commonly	encountered	in	routine	practice.		
Contrast-enhanced	T1	Mapping		
The	 use	 of	 gadolinium-based	 contrast	 agents	 shortens	 the	 native	 T1	 relaxation	 time	 of	 myo-
cardium	by	several	hundred	milliseconds.	Areas	with	a	disproportionate	accumulation	of	contrast	
material	 (fibrosis)	 will	 therefore	 exhibit	 shorter	 T1	 relaxation	 times	 than	 normal	 myocardium	
when	using	contrast-enhanced	T1	mapping	sequences	(Figure	6).	Whereas	nonenhanced	T1	map	
values	 are	 a	native	property	of	 the	myocardium,	 contrast-enhanced	T1	map	values	 are	 variable	


















In	 1988	 it	 was	 introduced	 a	 new	 CMR	 technique	 to	magnetically	 label	 or	 tag	 different	 regions	
within	the	heart	wall.	The	basic	 idea	was	to	create	noninvasive	markers	within	the	heart	wall	by	
applying	saturation	planes	perpendicular	to	the	imaging	plane	at	the	electrocardiographic	trigger	













tracking	 the	 motion	 of	 the	 tag	 lines	 throughout	 the	 cardiac	 cycle,	 the	 intramural	 myocardial	








should	 be	 as	 sharp	 as	 possible.	 For	 this	 purpose	 image	 quality	 is	 essential,	 whereas	 temporal	
resolution	 and	 the	 applicability	 of	 semiautomatic	 postprocessing	 become	 less	 important.	 This	
means	 for	 the	 image	acquisition	that	a	 rectangular	 intensity	profile	of	 the	tag	 lines	 is	preferred,	
and	that	grid-tagged	images	are	presented	to	the	observer.		





• The	 second	 type	 is	 based	 on	 optical	 flow,	 a	 method	 originating	 from	 machine	 vision	










Strain	 analysis	 describes	 the	 change	 of	 shape	 of	 material	 (i.e.,	 myocardium)	 resulting	 from	
deformation.	Strain	is	independent	of	rigid	body	motion	(translation	and/or	rotation)	and	does	not	
necessarily	need	an	external	reference	system.	
For	 interpretation	 of	 normal	 strains,	 a	 coordinate	 system	 is	 required.	 Two	 different	 coordinate	
systems,	 the	 radial/fiber/cross	 fiber	 system	 and	 the	 radial/circumferential/	 longitudinal	 system,	
are	used	for	this	purpose.	Using	this	coordinate	system,	myocardial	deformation	can	be	described	
in	a	more	intuitive	way:		


















The	 circumferential-longitudinal	 shear	 angle	 describes	 the	 twisting	 motion	 of	 the	 heart	 and	 is	
closely	related	to	torsion	of	the	LV.	
Cardiovascular	 magnetic	 resonance	 tissue	 tagging	 also	 offers	 the	 opportunity	 to	 quantify	
myocardial	 torsion	(Figure	8).	Torsion	 is	defined	as	 the	circumferential-longitudinal	shear	on	the	
epicardial	 surface	 between	 2	 short-axis	 slices.	 In	 the	 LV,	 torsion	 and	 untwisting	 is	 the	 result	 of	
contraction	and	relaxation	of	the	spiraling	myofibers.	
Figure	 8.	 Ventricular	 torsion	 and	 untwisting.	 Torsion	 and	 untwisting	 are	 the	 result	 of	 contraction	 and	





















information	 on	 the	 physiological	 significance	 of	 flow-limitation	 and	 sarcolemmal	 membrane	







can	 accurately	 assess	 both	 myocardial	 perfusion	 and	 ventricular	 function	 in	 diabetic	 patients,	
providing	 important	 information	 for	 their	 management.	 It	 also	 has	 high	 sensitivity	 in	
differentiating	 ischemic	 from	 non-ischemic	 cardiomyopathy.	 Nevertheless,	 factors	 other	 than	
coronary	 narrowing	 could	 play	 a	 role	 in	 the	 pathogenesis	 of	myocardial	 dysfunction	 in	 diabetic	




Among	 the	 available	 imaging	 modalities,	 only	 positron	 emission	 tomography	 (PET)	 allows	
quantitative	 assessment	 of	 myocardial	 blood	 flow	 using	 radiotracer	 kinetics.	 However,	 the	
combined	 images	 by	 MRI	 and	 PET	 provide	 a	 high	 spatial	 resolution	 detection	 of	 myocardial	
metabolic	abnormalities	and	currently	represent	the	most	valuable	imaging	analysis	for	diagnosis	
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contractility	 with	 the	 evolution	 to	 heart	 failure,	 independently	 of	 ischaemic	 heart	 disease	 or	
hypertension.	 Early	 stages	 of	 DCM	 are	 asymptomatic	 and	 characterized	 by	 various	 degrees	 of	
myocardial	 fibrosis.	 Our	 aim	 is	 to	 non-invasively	 detect	 myocardial	 fibrotic	 infiltration	 in	 DM-II	
patients,	 to	 assess	 its	 relationship	with	 ventricular	 function	 abnormalities	 and	 to	 compared	our	
results	with	a	group	of	healthy	controls.	
Methods	 and	 Materials:	 100	 patients	 affected	 by	 DM-II	 (57	 man,	 43	 women)	 with	 preserved	
ventricular	 function	 and	 no	 history	 of	 ischaemic	 disease	 and	 20	 matching	 controls	 underwent	
contrast	 cardiac	MR	 (CMR)	between	September	2014	and	 July	2017.	 Imaging	protocol	 included:	
modified	 Look-Locker	 sequence	 before	 and	 20	 minutes	 after	 a	 double	 dose	 of	 0.1	 mmol/kg	
gadoterate	 meglumine	 injection;	 T2-mapping;	 ventricular	 function	 module;	 tagged-cineMR	
module	and	 late	gadolinium	enhanced	(LGE)	 imaging.	Native	myocardial	T1	 (nT1)	and	T2	values,	




975±38	 ms,	 29.2±0.07%	 vs.	 22.8±4.3%	 respectively,	 p<0.05	 for	 both),	 whereas	 no	 significant	
differences	occurred	in	T2	measurements	(47.61±2.7ms	vs.	47.0±2.8ms	respectively,	p=0.23).	nT1	
and	 ECV	 correlated	 with	 HbA1c	 (nT1:	 r2=0.99,	 p<0.0001;	 ECV:	 r2=0,07;	 p<0.005)	 and	 disease	
duration	 (nT1:	 r2=0.99,	p<0.0001;ECV:	 r2=0,70	p<0,001)	 in	DM-II	patients.	nT1	and	ECV	correlate	
positively	torsion	(nT1:	r2=0.31,	p<0.001;	ECV:	r2=0.30;p<0.001)	and	negatively	with	strain	values	
in	 tagged-cineMR	analysis	 (nT1	with	global	 longitudinal	and	circunferential	 strain:	both	 r2=-0.97,	
p<0.0001;	 ECV:	 r2=0.63	 and	 r2=0.76,	 p<0.0001).	 LGE	 with	 ischemic	 pattern	 was	 found	 in	 eight	
patients	as	marker	of	silent	infarction.	
Conclusion:	 In	 DM-II	 patients	 with	 preserved	 ventricular	 function,	 HbA1c	 values	 and	 disease	
duration	 showed	 a	 significant	 correlation	 to	myocardial	 nT1	 and	 ECV	 increase,	 as	 reflection	 of	
diffuse	fibrosis,	and	geometrical	modification.	
INTRODUCTION	
Diabetic	 cardiomyopathy	 (DCM)	 is	 defined	 by	 the	 presence	 of	 structural	 and	 functional	
abnormalities	 of	 the	 myocardium	 in	 diabetic	 patients	 without	 coronary	 artery	 disease,		
hypertension,	congenital	or	valvular	heart	diseas	[1,2].	




produce	myocardial	 fibrosis	and/or	myocardial	hypertrophy:	 chronic	myocardial	 injury	 results	 in	
ventricular	 remodelling	 and	 progressive	 impairment	 of	 myocardial	 contraction	 (evolving	 from	
diastolic	to	combined	diastolic-systolic	dysfunction	[4,5].	
Early	recognition	of	DCM	in	pre-clinical	stage	is	currently	challenging	because	patients	are	usually	
asymptomatic	 and	 ventricular	 function	 and	morphology	 remains	 normal	 for	 ages	 appearing	 not	
easily	detectable	by	the	conventional	cardiovascular	imaging	exams	(echo,	CMR	and	scintigraphy)	
[6].	In	particular	subendocarial	dysfunction	is	the	first	sign	of	structural	changes	in	DCM	and	it	can	
be	 evaluated	 using	 conventional	 Doppler	 Echocardiography,	 tissue	 doppler	 imaging	 (TDI)	 and	




Cardiac	 Magnetic	 Resonance	 Imaging	 (CMR)	 compare	 to	 TEE	 provides	 extra-information	 about	
myocardial	fibrosis	and	subclinical	ischemia,	as	premature	parameters	of	cardiac	dysfunction.	CME	





Diffuse	 myocardial	 fibrosis	 can	 be	 indirectly	 assessed	 through	 geometrical	 modifications	 of	
myocardial	contraction	in	DCM	assessed	by	the	technique	of	tagging	MR	[12].	
Moreovere	 the	 new	 technique	 of	 T1	 mapping	 has	 been	 proposed	 as	 an	 objective	 method	 to	
directly	measure	the	signal	intensity	of	myocardium	before	the	administration	of	contrast	and	to	
measure	 myocardial	 extracellular	 matrix	 (ECM):	 this	 can	 be	 quantify	 in	 terms	 of	 extracellular	
volume	 fraction	 (ECV)	 after	 the	administration	of	 contrast	 [13].	 It	 provides	histologically-proven	
evidence	of	diffuse	 fibrosis	 in	a	broad	spectrum	of	cardiomyopathies,	 is	highly	 reproducible	and	
sensitive	[14-17].	In	particular	it	has	been	showed	a	significantly	shorter	global	contrast-enhanced	
myocardial	T1	 time	 in	diabetic	patients	compared	with	healthy	controls	and	 its	association	with	
more	impaired	longitudinal	myocardial	systolic	and	diastolic	function	[18,	19].	
In	 DCM	 the	 relationship	 between	 T1	 mapping	 parameters,	 functional	 and	 clinical	 parameters	
(HbA1c	and	duration	of	disease)	should	be	investigate.	
The	primary	aim	of	our	study	is	to	objectively	detect	and	quantify	the	diffuse	fibrotic	infiltration	of	
myocardium	 in	a	population	of	patients	with	diabetes	mellitus	 type	 II	 (DM-II)	using	T1	mapping	
technique	 and	 to	 compare	 these	 results	 to	 healthy	 controls.	 This	 study	 will	 also	 examine	 the	
correlations	between	global	 T1	 values	 (native	T1	and	ECV)	with	myocardial	 function	 (in	 term	of	






100	 patients	 affected	 by	 DM-II	 and	 20	 healthy	 controls	 were	 prospectively	 enrolled	 by	 the	
Department	 of	 Clinical	 and	 Molecular	 Endocrinology	 between	 April	 2014	 and	 July	 2017	 and	
classified	in	gender-based	age-matched	groups.	
Inclusion	criteria	were:	age	35-75	yrs;	HbA1c	<	10%;	normal	blood	pressure	(BP)	or	hypertension	
under	 pharmacological	 control	 by	 at	 least	 5	 years;	 BMI	 <	 40;	 diagnosis	 of	 diabetes	mellitus	 >	 3	
years.	
MR	Exclusion	criteria:		standard	contraindication	to	Magnetic	Resonance;	age	<	18	years;	severe	
arrhythmia	 or	 tachycardia;	 history	 of	 significant	 coronary	 artery	 disease,	 previous	 myocardial	
infarction	or	 cardiac	 inflammatory	disease;	 history	or	 evidence	 systemic	 autoimmune	disorders,	
sarcoidosis,	 amyloidosis	 or	 congenital	 heart	 disease;	 history	 or	 evidence	 of	 uncontrolled	
hypertension;	chronic	Kidney	disease	Stage	4	and	5	(GFR	<	30	mL/min/1.73m2)		













3.5	%)	were	enrolled	 as	 a	 control	 group;	 there	were	 included	patients	previously	 scheduled	 for	
CMR	with	other	 indications,	 such	as	arrhythmogenic	 right	ventricular	dysplasia,	non-compaction	
cardiomyopathy	or	atrial	fibrillation	and	with	CMR	negative	results.	
All	 subjects	 that	 during	 the	 CMR	 exam	 showed	 evidence	 of	 macroscopic	 late	 enhancement	
myocardial	areas	indicative	for	fibrosis/scar	from	previous	myocardial	infarction	were	excluded.	






- Breath-hold	ECG-gated	balanced-steady	state	 free	precession	 (bSSFP)	cine-MR	sequences	







- First	 pass	 imaging	 were	 acquired	 during	 the	 injection	 of	 0.1	 mmol/kg	 of	 Gadoterate	
meglumine.	
- Early	 gadolinium	enhanced	 images	were	 acquired	 by	 performing	 T1-weighted	 turbo	 spin	
echo	 sequence	 in	 four	 identical	 axial	 slices	 both	 before	 and	 three	 minutes	 after	
intravenous	administration	of	the	first	bolus	of	contrast	medium	in	order	to	evaluate	early	
myocardial	enhancement.	




- Traditional	 contrast-enhanced	 T1-weighted	 inversion	 recovery	 images	 were	 acquired	















HARP	software	tool	was	used	on	these	 images	 for	evaluating	myocardial	 strain	and	torsion.	The	









were	 	drawn	on	T2-STIR	 images	and	a	 reference	ROI	was	put	on	skeletal	muscle	 (i.e.	perctoralis	
muscle)	and	T2	ratio	was	calculated	as	previously	published	[20].	
1.3.4.	T2	mapping	analysis	












areas	 of	 enhancement	with	 coronary	 distribution	 and	 subendocardial	 involvement	 suggesting	 a	
previous	myocardial	 infarction,	as	 this	 is	an	esclusion	criteria.	However,	patients	with	 little	 focal	





patients	 without	 hypertension	 and	 DM	 patients	 with	 hypertension	 all	 study	 population	 was	
divided	in	two	subgroups	and	T1	mapping	values	were	separately	compared	to	HbA1c	levels	and	
duration	 of	 disease.	 Moreover	 all	 data	 collected	 were	 compared	 between	 DM	 II	 patients	 and	
controls.	
1.5	Statistical	analysis	
Statistical	 analysis	 was	 done	 using	 SPSS	 Software	 for	 Windows,version	 20.0	 (SPSS,Inc,Cary,NC	
package).	 All	 continuous	 variable	were	 expressed	 as	 average±SD.	 All	 correlations	were	 done	 by	





















Age	 66.8	±	5.1	 64.2	±	8.3	 0.60	




Glycemia		mg/dL		 133.7	±	43.1	 145.6	±	45.2	 0.21	
HbA1c		%		 6.7	±	1.0	 6.9	±	0.9		 0.32	
Trunk	fat	*		%		 34.5	±	3.6	 24.1	±	4.5	 0.00	
CrCl		mL/min		 94.5	±	26.6	 114.6	±	36.5	 0.19	
ASP		mmHg		 129.4	±	16.3	 124.7	±	13.1	 0.48	
ADP		mmHg		 71.6	±	9.1	 73.8	±	8.9	 0.32	
HR		batt/min		 74.5	±	12.6	 67.9	±	7.6	 0.08	
Age	of	disease	DM2	 11.9±	8	 13.2	±	8.1	 0.90	














Hypertension		 26	(61.9)		 32	(61.5)		 0.97	
Carotid	atherosclerosis	 5	(11.9)		 16	(30.8)		 0.45	
Dislipidemia	 30	(71.4)		 34	(61.5)		 0.66	






Diabetic	Nephropathy		 5	(11.9)		 12	(23.1)		 0.49	
Diabetic	Neuropathy		 5	(11.9)	 10	(19.2)		 0.3	
Diabetic	Retinopathy		 4	(9.5)		 2	(3.8)	 0.4	
11	(11%)	patients	were	excluded	from	the	analysis:	8	(8%)	because	of	the	evidence	of	macroscopic	













	 DM	II	(n=57)	 Controls	(n=43)	 p	
LV-EDVi	(mL/m2)	 55.02±13.8	 55±9.2	 n.s.	
LV-ESVi	(mL/m2)	 21.6±8.3	 18±8.3	 n.s.	
LV-SVi	(mL/m2)	 69.2±8.3	 51±10.8	 n.s.	
LV-EF	(%)	 62.6±7.5	 68±6.9	 n.s.	
LV-Mass(g/m2)	 80.7±10.7	 66±10.9		 <	0.05	
Global	Radial	Strain	(%)	 51.5±11.5	 		43.2±9.3	 <	0.01	
TD	(mm)	 46.6±5	 43.2±25	 0.003	
IVS	(mm)	 11.2±2.2	 10.2±2	 0.001	
Time-to-peak	Radial	Strain	(ms)	 299.2±38.2	 	322.5±48.7	 <	0.05	
Global	Circumferential	Strain(%)	 -22.5±5.3	 	-20.5±3.6	 <	0.01	
Time-to-peak	Circum	Strain	(ms)	 3013±41.8	 	322.6±48.7	 <	0.05	
Global	Longitudinal	Strain	(%)	 -18.4±4.4	 -	24.4±4.3	 <	0.01	
Time-to-peak	Long	Strain	(ms)	 321.6±50.6	 310.8±49.8	 <	0.05	






















There	 was	 an	 inverse	 correlation	 between	 T2	 map	 values	 in	 DM	 II	 patiens	 and	 HbA1c	 values	
(7.5±0.9;	r=-0.46;	p<0.0001),	while	no	correlation	was	observed	with	duration	of	disease.		









Graph	 2.	 Correlation	 between	 nT1	 (a)	 and	 ECV	 (b)	 vs	 Radial,	 Circumferential	 and	 Longitudinal	
Strain	
	








In	 our	 study	 we	 found	 significant	 differences	 between	 nT1	 and	 ECV	 in	 DM-II	 patients	 versus	
controls.	 In	 particular	 the	 difference	 in	 ECV	 between	 DM-II	 patients	 and	 controls	 confirmes	
previous	 studies	 [22]	 suggesting	 that	 extracellular	 matrix	 expansion	 could	 be	 considered	 an	
important	 intermediate	 phenotype	 in	 diabetic	 patients	 detectable	 by	 ECV	 and	 treatable.	 The	
increase	 of	 ECV	 in	 DM-II	 is	 due	 to	 proliferation	 of	 myofibroblast	 activated	 by	 glucose	 and	
myocardial	 fibrosis	 [6].	 Moreover	 ECV	 in	 diabetic	 people	 is	 associated	 with	 subclinical	 cardiac	
dysfunction	[23],	it	is	associated	with	higher	rate	of	adverse	outcomes	in	the	setting	of	diabetes.	In	
literature	results	on	ECV	and	DCM	are	controversial	[24]:	DM-II	is	expected	to	be	associated	with	
high	value	of	ECV,	but	 some	studies	 showed	 similar	 results	between	DM-II	patients	and	control	
[25,	26].	 In	 these	studies	patient	population	consisted	of	young	adults	or	selection	criteria	were	
too	much	limited.	
nT1	 and	 ECV	 showed	 a	 significant	 correlation	 with	 HbA1c	 and	 in	 particular	 with	 duration	 of	
disease.	 Fibrotic	 changes	 in	myocardium	 are	 associated	with	 duration	 of	 disease	 in	 animal	 and	




averaged	 glucose	 level.	 Hyperglycemia	 can	 cause	 persistent	 (a	 few	 days)	 damage	 to	 cells	 by	
disrupting	 the	 signal	 feedback	 loop	 [xx]	 and	 hyperglycemia	 can	 promote	 the	 proliferation	 of	
cardiac	 fibroblast	 [29,	30].	This	 result	 is	 in	conflict	with	previous	studies	 in	which	no	correlation	
was	found	between	fibrosis	and	HbA1c	and	for	this	reason	we	think	that	it	should	be	investigate	in	
future	studies	on	bigger	population	of	diabetic	patients		[31].	
No	 significant	 differences	 were	 found	 between	 nT1	 and	 ECV	 in	 DM-II	 patients	 without	
hypertension	and	DM-II	patients	with	hypertension	 (p=0.70;	p=0,67)	and	 this	 result	 support	 the	
idea	that	farmacological	control	of	hypertension	enables	to	stop	or	slow	down	the	progression	of	
DCM.	On	 the	other	hand	uncontrolled	hypertension	 is	associated	with	progression	of	DCM	as	 it	
has	been	investigated	in	previous	studies	[32].	
Our	 results	 showed	 a	 significant	 relationship	 between	 impaired	 left	 ventricle	 contractility	
measured	by	tagging	and	the	increased	ECV	despite	the	EF	conserved	in	DM-II	patients.	These	data	
confirmed	 a	 previous	 study	 done	 by	 our	 group	 on	 DM-II	 patients	 [12]	 in	 which	 we	 found	 an	
uncoupling	between	longitudinal	and	circunferential	strain	and	a	resultant	modification	of	torsion	





LGE	 observed	 in	 8	 DM-II	 patients	 confirmed	 the	 capability	 of	 CMR	 to	 see	macroscopic	 area	 of	
fibrosis	 due	 to	 silent	myocardial	 ischemia	 (SMI)	 or	myocardial	 infarction	 (MI).	 This	 entity	 is	 an	
important	clinical	entity,	it	is	common	in	patients	with	diabetes	and	it	is	an	independent	predictor	
of	mortality	 [33].	 Its	 recognition	may	 lead	 to	early	 intervention	and	 changes	prognosis	of	 these	
patients.	In	a	substudy	of	the	Diabetes	Control	and	Complications	Trial	it	has	been	demonstrated	a	
4.3%	prevalence	of	LGE	consistent	with	unrecognized	MI	in	patients	with	type	1	diabetes	without	




Nobody	 of	 DM	 II	 patients	 showed	 myocardial	 edema	 on	 T2	 images	 and	 T2	 mapping	 values	
confirmed	 the	 absence	 of	 edematous	 changes	 in	 myocardium.	 We	 used	 T2	 mapping	 to	 verify	
results	of	 the	 standard	measurements	done	with	T2-STIR	 images	 [36].	Moreover	 there	were	no	
significant	difference	between	DM	II	patients	and	controls.	
Our	 study	 has	 some	 limitations:	 first	 of	 all	 we	 need	 to	 collect	 data	 on	 a	 bigger	 population	 of	
diabetic	patients;	second	we	did	not	recruit	patients	with	a	GFR	≤	30	mL/min/1.7m2	,	and	it	should	










mapping.	 This	 method	 could	 be	 useful	 in	 the	 detection	 of	 interstitial	 fibrosis	 and	 in	 the	 early	
diagnosis	of	DCM.	 In	particular	 it	could	add	value	to	the	technique	of	MR-tagging	because	of	 its	
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